MediciNova's Krabbe therapy gets rare pediatric designation

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said FDA granted rare pediatric disease designation to ibudilast ( MN-166), its candidate to treat globoid cell leukodystrophy, or Krabbe disease. The designation is among the criteria that would make MediciNova eligible for a Priority Review voucher under FDA's rare pediatric disease voucher program, if the therapy is approved.

Ibudilast has Orphan Drug designation from FDA in the same indication. MediciNova did not respond to an inquiry about its development phase. ...